N@N

Eclipsys to Present at the Bank of America Merrill Lynch Health Care Conference

^{Published on 2010-05-08 09:00:13 - Market Wire}
 

ATLANTA--([ BUSINESS WIRE ])--Eclipsys Corporation (NASDAQ: ECLP), The Outcomes Company^®, will be participating in the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 12, in New York, NY.

"Management's Discussion and Analysis of Financial Condition and Results of Operations."

Eclipsysa" representatives will present at the conference at 3:00 p.m. Eastern time. Interested parties are invited to listen to the presentation via webcast at: [ https://www.veracast.com/webcasts/bas/healthcare2010/id18977260.cfm ]

Listeners are encouraged to log on to the Web site approximately 10 minutes prior to the presentation start time to download the necessary software. A replay of the webcast will be archived in the Investor Relations area of the Eclipsys Web site following the presentation.

About Eclipsys

Eclipsys is a leading provider of advanced integrated clinical, revenue cycle and performance management software, clinical content and professional services that help healthcare organizations improve clinical, financial and operational outcomes. For more information, see [ www.eclipsys.com ] or email [ info@eclipsys.com ].

Management's prepared remarks and answers to questions during the presentation referenced in this release, including those concerning the company's financial results, operational initiatives, future performance expectations, and effects of economic conditions are forward-looking statements and actual results may differ materially from those projected or implied by the forward-looking statements due to a variety of risks and uncertainties. Future performance expectations are predicated upon achievement of various sales and performance targets that may be difficult to meet. Economic conditions are unstable and may cause hospitals and other healthcare providers to curtail HIT system spending. Eclipsys' cost reduction and other initiatives in response to the challenging economic environment, including initiatives designed to improve operational efficiencies, may not be effective, and it is difficult to predict what the company may be able to achieve. Eclipsys sales may fall below expectations due to market conditions, competition, and other factors, including client demands for pricing and financing concessions. Costs may be greater than anticipated due to the potential need to increase spending to ensure performance in accordance with commitments to clients, regulatory requirements and other factors. Software development may take longer and cost more than expected, and incorporation of anticipated features and functionality (including as required to comply with ARRA and related regulations, as well as other certification standards) may be delayed, due to various factors including programming and integration challenges and resource constraints. The market is highly competitive. Implementation and customization of Eclipsys software is complex and time-consuming. Results depend upon a variety of factors and can vary by client. Each client's circumstances are unique and may include unforeseen issues that make it more difficult than anticipated to implement or derive benefit from software, implementation or consulting services. The success and timeliness of the company's services will depend at least in part upon client involvement, which can be difficult to control. Eclipsys is required to meet specified performance standards and regulatory requirements, and clients can terminate contracts, assess penalties or reduce contract scope under certain circumstances. More information about company risks is available in recent Form 10-K and other filings made by Eclipsys from time to time with the Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations."

Eclipsys and The Outcomes Company are either registered trademarks or trademarks of Eclipsys Corporation (or its subsidiaries) in the United States and certain other countries.